Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6056718 | Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology | 2015 | 7 Pages |
Abstract
Mammalian targets of rapamycin inhibitors (mTOR inhibitors, mTORI) are indicated for the management of several cancer types, including hormone receptor-positive or HER2-negative breast cancer, advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, and tuberous sclerosis complex-related tumors. Among the most common adverse events of mTORI medication are discrete, large, solitary or multiple, superficial ulcers, almost exclusively situated on nonkeratinized oral mucosa, described as mTORI-associated stomatitis (mIAS). We describe the clinical presentation, course, and management of mIAS in three patients receiving the mTORI everolimus (Afinitor, Novartis, East Hanover, NJ). In two patients, mIAS manifested 9 and 30Â days after first using everolimus, respectively, whereas in the third patient, it recurred 3Â months after re-introduction of everolimus. Oral rinses with a “magic mouthwash” solution (dexamethasone oral drops solution 2Â mg/mLÂ Ã 10 mL, lidocaine gel 2%Â Ã 30 g, doxycycline suspension 50 mg/5 mLÂ Ã 60 mL, and sucralfate oral suspension 1000 mg/5 mLÂ Ã 150 mL, dissolved in sodium chloride 0.9%Â Ã 2000 mL) four times daily proved helpful in alleviating the symptoms, and the ulcers healed in 4 to 15Â days. No side effects were recorded, and dose reduction or discontinuation of everolimus was not necessitated in two cases.
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Eleni-Marina DDS, Konstantinos I. DDS, PhD, Evangelia P. DDS, MSc, PhD, Alexandra DDS, MSc, PhD,